drugset / Trial / NCT01253837
L19TNFα in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues. Tumor-targeted L19TNFα would result in high and sustained intralesional bioactive TNFα concentrations.
Timeline
- Start
- 2007-09
- Primary completion
- 2011-05
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L19TNFa | Monoclonal antibody | 1.3 ug/kg | — |
| Subject | L19TNFa | Monoclonal antibody | 2.6 ug/kg | — |
| Subject | L19TNFa | Monoclonal antibody | 5.2 ug/kg | — |
| Subject | L19TNFa | Monoclonal antibody | 7.8 ug/kg | — |
| Subject | L19TNFa | Monoclonal antibody | 10.4 ug/kg | — |
| Subject | L19TNFa | Monoclonal antibody | 13 ug/kg | — |